We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BNZL:LSEBunzl plc Analysis

Data as of 2026-03-11 - not real-time

£2,234.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Bunzl plc trades around £2,234, roughly 12% above the DCF‑derived fair value of £1,938, indicating a near‑term pricing premium. The stock benefits from a solid 3.32% dividend yield supported by a comfortable 52.5% payout ratio and robust free cash flow, while technicals show a bullish bias – price sits above the 20‑day (2,167) and 50‑day (2,110) SMAs, MACD is bullish and RSI at 61 suggests upward momentum without being overbought. However, revenue growth is flat at 0.3% and margins remain modest, with a gross margin of only 7.7%. Recent news flags challenges in North America, noting that the group is “undoing the damage” and that rebuilding credibility will take time, adding a layer of operational uncertainty.
Given the low beta of 0.18 and a 30‑day volatility of 21.5%, market‑related risk is limited, but the combination of an overvalued price relative to fundamentals, modest growth prospects, and sector‑specific regulatory exposure suggests a cautious stance. The dividend remains sustainable, yet the high price‑to‑book multiple (≈258×) and the modest upside potential temper enthusiasm for new buying, especially for longer horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and price above short‑term moving averages
  • RSI at 61 indicating room for upside without overbought pressure
  • Proximity to resistance around £2,270 limiting immediate upside

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Dividend yield of 3.32% with a sustainable payout ratio
  • Flat revenue growth and modest margins reducing earnings upside
  • Current price trading ~12% above DCF fair value

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Overvaluation relative to DCF and high price‑to‑book multiple
  • Limited revenue growth prospects in a mature consumer‑defensive sector
  • Operational headwinds in North America affecting future credibility

Key Metrics & Analysis

Financial Health

Revenue Growth0.30%
Profit Margin3.88%
P/E Ratio15.8
ROE16.47%
ROA5.25%
Debt/Equity105.93
P/B Ratio258.2
Op. Cash Flow£913.0M
Free Cash Flow£615.8M

Technical Analysis

TrendNeutral
RSI61.7
Support£2,090.00
Resistance£2,270.00
MA 20£2,167.40
MA 50£2,109.82
MA 200£2,261.28
MACDBullish
VolumeIncreasing
Fear & Greed Index75.86

Valuation

Fair Value£1,938.11
Target Price£2,506.19
Upside/Downside12.18%
GradeOvervalued
TypeValue
Dividend Yield3.32%

Risk Assessment

Beta0.18
Volatility21.58%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.